INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Sun Pharmaceutical Industries
Back to Newsroom
🏢Organization Dossier

Sun Pharmaceutical Industries

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

8 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Markets, IPOs & Wealth 17 Nov 2026, 02:00 PM IST

Sun Pharma Shares Track Market Mood as Investors Reprice Pharma Risk and Growth

Sun Pharmaceutical Industries’ share price was in focus in afternoon trade as investors weighed the stock’s near-term momentum against broader market cues, sector rotation, and expectations around earnings visibility. The move comes at a time when large-cap pharmaceutical counters remain sensitive to global demand trends, pricing pressure in key export markets, and domestic risk appetite.

By RDU Global Wire5 min read
Healthcare, Pharma & Life Sciences01 Nov 2026, 02:00 PM IST

Sun Pharma Q2 Profit Falls 36% as Litigation and Deal Costs Weigh on Earnings

Sun Pharmaceutical Industries reported a 36% drop in second-quarter net profit to Rs 1,989 crore, as exceptional litigation and acquisition-related expenses sharply reduced earnings. Revenue rose 11.8% on the back of strong domestic and emerging-market demand, but weakness in the US formulations business tempered the overall performance.

4 min readRead →
Markets, IPOs & Wealth05 Nov 2026, 02:00 PM IST

Sun Pharma Shares in Focus as Traders Track Current Price Action Amid Broader Market Caution

Sun Pharmaceutical Industries Ltd. is drawing close market attention as investors monitor its live share price against a backdrop of cautious trading across Indian equities. The stock’s movement is being read not just as a company-specific signal, but also as a gauge of sentiment toward large-cap healthcare names in a volatile macro environment. With fiscal and macroeconomic cues still shaping risk appetite, Sun Pharma’s current trading pattern is likely to remain under scrutiny from institutional and retail investors alike. Market participants are watching for whether the counter can sustain momentum, consolidate, or face pressure from broader sector rotation.

5 min readRead →
Healthcare, Pharma & Life Sciences19 Nov 2026, 05:00 PM IST

Health Ministry Proposes Drug Rules Amendment to Ease Regulation of Medicinal Gases, Empty Gelatin Capsules and Disinfectant Liquids

India’s Health Ministry has proposed amendments to the Drugs Rules, 1945, aimed at introducing greater regulatory flexibility for medicinal gases, empty gelatin capsules and disinfectant liquids. The move signals a broader effort to streamline compliance while preserving quality and safety oversight across essential pharmaceutical inputs.

5 min readRead →
Global Markets & Equities17 Nov 2026, 05:00 PM IST

Nationwide Recall Issued for Blood Pressure Drug Over Possible Metal Contamination

A U.S. manufacturer has initiated a nationwide consumer-level recall of a blood pressure medication after identifying a potential metal contamination risk in one lot of the product. The action adds to a growing list of pharmaceutical quality-control incidents that can disrupt supply chains, unsettle patients, and draw heightened scrutiny from regulators and wholesalers.

5 min readRead →
Markets, IPOs & Wealth17 Nov 2026, 02:00 PM IST

Dr. Reddy’s Shares Edge Higher in Cautious Trade as Investors Reassess Pharma Valuations

Dr. Reddy’s Laboratories saw a modest uptick in its share price in afternoon trade, reflecting a measured rebound in a sector that has been under close scrutiny for pricing, earnings visibility and export demand. The move was not dramatic, but it signalled that investors remain willing to accumulate quality pharmaceutical names on dips even as broader market sentiment stays selective.

5 min readRead →
Global Markets & Equities13 Nov 2026, 02:00 PM IST

Pfizer Secures $1.5 Billion Blackstone Backing to Advance Weight-Loss Drug Push

Pfizer has struck a financing agreement with Blackstone worth up to $1.5 billion to support development of its obesity-drug program, according to reports. The deal underscores how major pharmaceutical companies are increasingly leaning on private capital to help fund high-cost, high-risk drug pipelines as competition intensifies in the booming weight-loss market.

5 min readRead →
Markets, IPOs & Wealth07 Nov 2026, 02:00 PM IST

Divis Labs Share Price in Focus as Investors Reassess the Stock’s Long-Term Trajectory

Divis Laboratories has drawn renewed market attention as investors revisit the company’s share price history, business resilience, and valuation profile in a shifting macroeconomic environment. The stock remains closely watched for signals on how defensive pharmaceutical names are being priced amid broader volatility in Indian equities.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Sun Pharmaceutical Industries: